Docetaxel as a single agent in first-line therapy of non-small cell lung cancer

Onkologie

Volumn 23, Issue SUPPL. 6, 2000, Pages 16-17

  Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; TUBULIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; LUNG NON SMALL CELL CANCER; MUTATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN PHOSPHORYLATION;

EID: 0033767911     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055068     Document Type: Conference Paper

References (4)

1. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
2. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study
3. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer
4. Sequential chemotherapy: Rationale and clinical trial design in advanced non-small-cell lung carcinoma